FDA Approves Onswik, a Once-Weekly Basal Insulin for Adults With Type 2 Diabetes

The U.S. Food and Drug Administration has approved Onswik (insulin efsitora alfa-gobe), a new once-weekly basal insulin for adults with type 2 diabetes. Developed by Eli Lilly and Company, Onswik is intended to be used alongside diet and exercise to help improve blood sugar control.

The approval introduces another treatment option for adults who require basal insulin while potentially reducing the number of injections needed. Unlike conventional basal insulin regimens that may require an injection every day, Onswik is administered once a week and is designed to provide basal insulin coverage across seven days.

What Is Onswik?

Onswik is the brand name for insulin efsitora alfa-gobe, a long-acting basal insulin developed for adults with type 2 diabetes. It is administered by subcutaneous injection once each week.

Basal insulin is used to help manage blood glucose between meals and throughout the day and night. With a weekly formulation, Onswik aims to provide this background insulin effect while requiring fewer injections.

According to the source announcement, switching from a once-daily basal insulin schedule to a once-weekly treatment could eliminate more than 300 injections per year. This reduced injection frequency may offer a more convenient option for some adults who need insulin therapy.

Onswik is not approved for people with type 1 diabetes, and its safety and effectiveness in children have not been established.

Clinical Trials Supporting FDA Approval

The FDA approval of Onswik was supported by Lilly's QWINT Phase 3 clinical development program. The program included more than 3,400 adults with type 2 diabetes and evaluated the efficacy and safety of once-weekly insulin efsitora alfa-gobe.

Across the QWINT trials, Onswik achieved the primary endpoint of non-inferior reductions in A1C compared with daily basal insulin treatments, including insulin glargine U-100 and insulin degludec U-100. In other words, the trials were designed to determine whether the weekly insulin's ability to lower A1C was not meaningfully worse than the daily insulin comparators within the studies' predefined statistical margins.

The QWINT program included adults at different stages of insulin treatment. For example, QWINT-1 studied insulin-naive adults and compared weekly efsitora with daily insulin glargine over 52 weeks. QWINT-2 compared weekly efsitora with daily insulin degludec in 928 insulin-naive adults.

Other studies included people already receiving basal insulin. QWINT-3 evaluated adults previously treated with basal insulin, while QWINT-4 studied adults who had previously received basal insulin alongside multiple daily mealtime insulin injections.

Why Once-Weekly Insulin Could Matter

Daily injections can add to the practical burden of diabetes management. A basal insulin that only needs to be administered once every seven days significantly reduces injection frequency.

For people prescribed basal insulin, a weekly schedule could potentially make treatment routines simpler. However, fewer injections do not mean that blood glucose monitoring or careful insulin management becomes unnecessary.

People using Onswik still need to follow the dosing instructions given by their healthcare provider and monitor their blood sugar as advised. Insulin requirements can also change because of factors such as physical activity, diet, illness, stress, weight changes and other medications.

Patients should not change their insulin type or dose without appropriate guidance from their healthcare provider.

How Is Onswik Taken?

Onswik is injected under the skin once each week, preferably on the same day every week. Approved injection areas include the abdomen, buttocks, thigh and back of the upper arms.

Injection locations should be rotated rather than repeatedly using exactly the same spot. The medicine should not be administered through an insulin pump or injected into a vein or muscle.

The source prescribing information also contains specific instructions for missed doses and changing the usual injection day. Because weekly insulin dosing differs substantially from daily insulin schedules, patients should follow the instructions supplied with their prescription and the directions provided by their healthcare professional.

Onswik KwikPen Dosage Strengths

The Onswik KwikPen is expected to become available in the United States in two concentrations: 500 units/mL and 1,000 units/mL.

The U-500 prefilled pen contains 1,500 total units and can deliver doses in 5-unit increments, with up to 400 units in a single injection. The U-1,000 pen contains 3,000 total units and delivers doses in 10-unit increments, with up to 800 units in a single injection.

These high concentrations make accurate dosing particularly important. Patients should always verify that they have the correct insulin and prescribed dose before administering an injection. The source specifically warns against withdrawing Onswik from the pen using a syringe.

Onswik Side Effects and Safety Information

Low blood sugar, or hypoglycemia, is an important risk associated with insulin treatment. Symptoms can include dizziness, confusion, shakiness, sweating, hunger, blurred vision, a fast heartbeat and headache.

The reported common side effects of Onswik include hypoglycemia, allergic reactions, injection-site reactions, itching, rash, weight gain, swelling of the hands and feet, and lipodystrophy, which can cause thickened or pitted skin around injection areas.

More serious potential adverse effects include severe allergic reactions and low potassium levels. The safety information also warns about heart failure when insulin is taken with certain diabetes medicines known as thiazolidinediones, or TZDs.

Onswik should not be taken during an episode of hypoglycemia or by someone who is allergic to insulin efsitora alfa-gobe or any ingredient in the medication.

Another Once-Weekly Option for Type 2 Diabetes

The U.S. authorization follows regulatory actions involving Onswik in other markets, including Europe, Mexico and Japan. In the United States, the Onswik KwikPen is expected to become available in the coming months, according to the source announcement.

The FDA approval represents an important development in long-acting insulin therapy because it gives eligible adults with type 2 diabetes an alternative to daily basal insulin injections. Whether it is appropriate for a particular patient depends on individual treatment needs, blood glucose management, other medications and medical history.

People considering Onswik should discuss its potential benefits, risks and dosing requirements with their healthcare provider rather than changing an existing insulin regimen independently.

Source: Eli Lilly and Company's September 24, 2026 announcement regarding the FDA approval of Onswik (insulin efsitora alfa-gobe), including information about the QWINT Phase 3 clinical trial program and the medication's indication and safety summary.

Medical disclaimer: This article is provided for general informational and educational purposes only and is not medical advice. It is not intended to diagnose, treat, cure or prevent any medical condition and should not replace advice from a qualified healthcare professional. Insulin can cause serious adverse effects, including severe hypoglycemia. Do not start, stop, switch or change the dose or schedule of insulin or another diabetes medication without consulting your healthcare provider.